Ratings BioLargo, Inc.

Equities

BLGO

US09065A1007

Market Closed - OTC Markets 03:58:31 2024-06-05 pm EDT 5-day change 1st Jan Change
0.272 USD -1.98% Intraday chart for BioLargo, Inc. -9.63% +61.90%

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.

Ratings chart - Surperformance

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+61.90% 82.37M -
+4.86% 104B
A-
-10.06% 60.79B
A-
+64.76% 51.13B
B
+14.74% 38.21B
B
-0.02% 30.75B
A-
+11.82% 19.83B
B-
+10.49% 16.5B
C+
+7.90% 13.82B
B-
-4.54% 13.33B
B
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. BLGO Stock
  4. Ratings BioLargo, Inc.